Skip to main content
SpringerLink
Log in

Chemotherapy

  • Chapter
  • First Online:
Upper Tract Urothelial Carcinoma

  • 640 Accesses

Abstract

Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer. 1987;60(3 Suppl):574–85.

    Article  PubMed  CAS  Google Scholar 

  2. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15(3):127–39.

    Article  PubMed  Google Scholar 

  3. Tzai TS, et al. Clinical significance of allelotype profiling for urothelial carcinoma. Urology. 2003;62(2):378–84.

    Article  PubMed  Google Scholar 

  4. Hafner C, et al. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101(1):1–6.

    Article  PubMed  CAS  Google Scholar 

  5. Hafner C, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20(35):4910–5.

    Article  PubMed  CAS  Google Scholar 

  6. Jones TD, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11(18):6512–9.

    Article  PubMed  CAS  Google Scholar 

  7. Catto JW, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol. 2007;177(5):1715–20.

    Article  PubMed  CAS  Google Scholar 

  8. Akdogan B, et al. Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol. 2006;176(1):48–52.

    Article  PubMed  Google Scholar 

  9. Kaufman DS, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004;22(5):393–7.

    Article  PubMed  CAS  Google Scholar 

  10. von der Maase H, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.

    PubMed  Google Scholar 

  11. Sternberg CN, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10):2638–46.

    PubMed  CAS  Google Scholar 

  12. Bamias A, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22(2):220–8.

    Article  PubMed  CAS  Google Scholar 

  13. Kaufman D, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921–7.

    PubMed  CAS  Google Scholar 

  14. Dreicer R, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100(8):1639–45.

    Article  PubMed  CAS  Google Scholar 

  15. Grossman HB, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  PubMed  CAS  Google Scholar 

  16. Griffiths G, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–7.

    Article  PubMed  CAS  Google Scholar 

  17. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354(9178):533–40.

    Google Scholar 

  18. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–34.

    Google Scholar 

  19. Kitamura H et al. Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209. J Clin Oncol. 2013;31(suppl 6; abstr 249).

    Google Scholar 

  20. Margulis V, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224–33.

    Article  PubMed  Google Scholar 

  21. Keeley FX, et al. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cellcarcinoma. J Urol. 1997;157(1):33–7.

    Article  PubMed  CAS  Google Scholar 

  22. Williams SK, et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol. 2008;22(1):71–6.

    Article  PubMed  Google Scholar 

  23. Brown GA, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007;70(2):252–6.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Skolarikos A, et al. Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology. 2003;61(6):1146–50.

    Article  PubMed  CAS  Google Scholar 

  25. Fritsche HM, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol. 2012;30(5):666–72.

    Article  PubMed  Google Scholar 

  26. Remzi M, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103(3):307–11.

    Article  PubMed  Google Scholar 

  27. Kikuchi E, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27(4):612–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bolenz C, et al. Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. Urology. 2008;72(2):364–9.

    Article  PubMed  Google Scholar 

  29. Kim DS, et al. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology. 2010;75(2):328–32.

    Article  PubMed  Google Scholar 

  30. Hurel S, et al. Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2013;111(8):1199–207.

    Article  PubMed  Google Scholar 

  31. Ito Y, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2011;185(5):1621–6.

    Article  PubMed  Google Scholar 

  32. Matin SF, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010;116(13):3127–34.

    Article  PubMed  Google Scholar 

  33. Splinter TA, et al. A European Organization for Research and Treatment of Cancer–Genitourinary Group phase 2 study of chemotherapy in stage T3–4N0–XM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol. 1992;148(6):1793–6.

    PubMed  CAS  Google Scholar 

  34. Porten SP, et al. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. J Clin Oncol. 2013;31(suppl 6; abstr 311).

    Google Scholar 

  35. Siefker-Radtke A, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol. 2012;30(suppl; abstr 4523).

    Google Scholar 

  36. Gray P, et al. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: associations with clinical variables and survival. J Clin Oncol. 2013;31(suppl 6; abstr 248).

    Google Scholar 

  37. Kaag MG, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581–7.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hellenthal NJ, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009;182(3):900–6.

    Article  PubMed  Google Scholar 

  39. Kwak C, et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology. 2006;68(1):53–7.

    Article  PubMed  Google Scholar 

  40. Stadler WM, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29(25):3443–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):89–199. discussion 199–201.

    Google Scholar 

  42. Paz-Ares LG et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol. 2008;28:18s, 2010 (suppl; abstr LBA4518).

    Google Scholar 

  43. Bamias A, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22(11):2150–4.

    Article  PubMed  CAS  Google Scholar 

  44. Hall MC, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52(4):594–601.

    Article  PubMed  CAS  Google Scholar 

  45. Siefker-Radtke AO, et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013;119(3):540–7.

    Article  PubMed  CAS  Google Scholar 

  46. Bajorin DF, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 2000;88(7):1671–8.

    Article  PubMed  CAS  Google Scholar 

  47. Bellmunt J, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  48. Logothetis CJ, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8(6):1050–5.

    PubMed  CAS  Google Scholar 

  49. Balar AV, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31(6):724–30.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Galsky MD, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–4.

    Article  PubMed  Google Scholar 

  51. Pagliaro L, et al. Gemcitabine, paclitaxel, and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. J Clin Oncol. 2011;29(suppl 7; abstr 246).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, NYU Perlmutter Cancer Center, 160 E 34th Street 8th Floor, New York, NY, 10016, USA

    Arjun Vasant Balar MD

  2. Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY, 10029, USA

    Matthew D. Galsky MD

  3. The M. D. Anderson Cancer Center, 1155 Pressler, Unit 1374, CPB7.3508, Houston, TX, 77030, USA

    Arlene O. Siefker-Radtke MD

  4. Weill Cornell Cancer Center, Weill Cornell Medical College, 525 E 68th Street, New York, NY, 10065, USA

    Scott T. Tagawa MD, MS

  5. UNC Lineberger Comprehensive Cancer Center, 3rd Floor Physicians Office Building, 170 Manning Drive, Chapel Hill, NC, 27599, USA

    Matthew I. Milowsky MD

Authors
  1. Arjun Vasant Balar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew D. Galsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arlene O. Siefker-Radtke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott T. Tagawa MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew I. Milowsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew I. Milowsky MD .

Editor information

Editors and Affiliations

  1. Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    Shahrokh F. Shariat

  2. Department of Urology, Paris Descartes University, Paris, France

    Evanguelos Xylinas

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Balar, A.V., Galsky, M.D., Siefker-Radtke, A.O., Tagawa, S.T., Milowsky, M.I. (2015). Chemotherapy. In: Shariat, S., Xylinas, E. (eds) Upper Tract Urothelial Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1501-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1501-9_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1500-2

  • Online ISBN: 978-1-4939-1501-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation